整合临床与病理特征及31基因表达谱检测以优化皮肤黑色素瘤患者的治疗策略
研究基于I-III期皮肤黑色素瘤队列(开发n=1581,验证n=523)建立整合31基因表达谱与临床病理数据的复发风险算法(i31-ROR),低风险组5年无复发生存率91% vs 高风险组45%(P < .001);联合i31-SLNB分析可识别44%可免于前哨淋巴结活检且生存率高的患者。
要点
- 低风险i31-ROR组5年无复发生存率91% vs 高风险组45%(P < .001)。
- 低风险i31-ROR组5年无远处转移生存率95% vs 高风险组53%(P < .001)。
- 联合i31-SLNB/ROR分析识别44%可免于前哨淋巴结活检且生存率>98%的患者。
核心结论
- 将临床病理特征与31基因表达谱整合,相比单独使用临床病理特征可优化患者风险分层。
研究设计与样本
- 开发Cox回归模型(n=1581)并在I-III期黑色素瘤队列中独立验证(n=523)。
- 采用美国国家综合癌症网络(NCCN)切点,以IIA期与IIB期患者的中点生存率作为风险阈值评估i31-ROR性能。
主要发现
- 低风险i31-ROR组5年无复发生存率91% vs 高风险组45%(P < .001)。
- 低风险i31-ROR组5年无远处转移生存率95% vs 高风险组53%(P < .001)。
- 低风险i31-ROR组5年黑色素瘤特异性生存率98% vs 高风险组73%(P < .001)。
- 联合i31-SLNB/ROR分析识别44%可免于前哨淋巴结活检且维持高生存率(>98%)的患者,或将其重新分层为复发或死亡风险更高或更低。
关键数值与推荐
- 低风险i31-ROR组5年无复发生存率91% vs 高风险组45%(P < .001)。
- 低风险i31-ROR组5年无远处转移生存率95% vs 高风险组53%(P < .001)。
- 低风险i31-ROR组5年黑色素瘤特异性生存率98% vs 高风险组73%(P < .001)。
- 联合i31-SLNB/ROR分析识别44%可免于前哨淋巴结活检且维持高生存率(>98%)的患者。
临床怎么用
- 原文未据此给出推荐。
局限性
- 多中心、回顾性研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Many patients with low-stage cutaneous melanoma will experience tumor recurrence, metastasis, or death, and many higher staged patients will not. OBJECTIVE: To develop an algorithm by integrating the 31-gene expression profile test with clinicopathologic data for an optimized, personalized risk of recurrence (integrated 31 risk of recurrence [i31-ROR]) or death and use i31-ROR in conjunction with a previously validated algorithm for precise sentinel lymph node positivity risk estimates (i31-SLNB) for optimized treatment plan decisions. METHODS: Cox regression models for ROR were developed (n = 1581) and independently validated (n = 523) on a cohort with stage I-III melanoma. Using National Comprehensive Cancer Network cut points, i31-ROR performance was evaluated using the midpoint survival rates between patients with stage IIA and stage IIB disease as a risk threshold. RESULTS: Patients with a low-risk i31-ROR result had significantly higher 5-year recurrence-free survival (91% vs 45%, P < .001), distant metastasis-free survival (95% vs 53%, P < .001), and melanoma-specific survival (98% vs 73%, P < .001) than patients with a high-risk i31-ROR result. A combined i31-SLNB/ROR analysis identified 44% of patients who could forego sentinel lymph node biopsy while maintaining high survival rates (>98%) or were restratified as being at a higher or lower risk of recurrence or death. LIMITATIONS: Multicenter, retrospective study. CONCLUSION: Integrating clinicopathologic features with the 31-GEP optimizes patient risk stratification compared to clinicopathologic features alone.
引用
- Jarell A, Gastman BR, Dillon LD, et al. Optimizing treatment approaches for patients with cutaneous melanoma by integrating clinical and pathologic features with the 31-gene expression profile test. J Am Acad Dermatol. 2022. PMID: 35810840. doi:10.1016/j.jaad.2022.06.1202
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。